CU23636A1 - Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) - Google Patents

Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)

Info

Publication number
CU23636A1
CU23636A1 CU20060208A CU20060208A CU23636A1 CU 23636 A1 CU23636 A1 CU 23636A1 CU 20060208 A CU20060208 A CU 20060208A CU 20060208 A CU20060208 A CU 20060208A CU 23636 A1 CU23636 A1 CU 23636A1
Authority
CU
Cuba
Prior art keywords
vegf
molecules
growth factor
vitro
endotelium
Prior art date
Application number
CU20060208A
Other languages
English (en)
Inventor
Ordas Humberto Lamdan
Santiago Glay Chinea
Cruz Osmany Guirola
Avila Marta Ayala
Dorantes Gertrudis Rojas
Diaz Yanelis Morera
Vispo Nelson Francisco Santiago
Cowley Jorge Victor Gavilondo
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20060208A priority Critical patent/CU23636A1/es
Priority to BRPI0717971-5A2A priority patent/BRPI0717971A2/pt
Priority to CA002667594A priority patent/CA2667594A1/en
Priority to EP07817383A priority patent/EP2093236A1/en
Priority to CNA2007800437331A priority patent/CN101573379A/zh
Priority to KR1020097011229A priority patent/KR20090078363A/ko
Priority to MX2009004765A priority patent/MX2009004765A/es
Priority to RU2009120536/10A priority patent/RU2009120536A/ru
Priority to PCT/CU2007/000019 priority patent/WO2008052489A1/es
Priority to JP2009534978A priority patent/JP2010508033A/ja
Priority to AU2007315484A priority patent/AU2007315484A1/en
Priority to US12/447,711 priority patent/US20100151566A1/en
Priority to ARP070104873A priority patent/AR063448A1/es
Priority to ZA200903017A priority patent/ZA200903017B/xx
Priority to CO09056360A priority patent/CO6341480A2/es
Publication of CU23636A1 publication Critical patent/CU23636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Moléculas polipeptídicas recombinantes relacionadas con anticuerpos, que reconocen específicamente el Factor de Crecimiento de Endotelio Vascular-A (VEGF-A) humano, e interfieren con sus efectos estimulatorios in vitro, y proangiogénicos in vivo. Dichas moléculas polipeptídicas recombinantes son capaces de afectar la proliferación de células endoteliales humanas in vitro, la angiogénesis subcutánea en ratones inducida por tapones de Matrigel que contienen VEGF-A, y el crecimiento de tumores humanos trasplantados a ratones desnudos. Varias de estas moléculas previenen la neovascularización coroidea en un modelo experimental en primates no humanos. Estas moléculas pueden emplearse para inmunoterapia pasiva de entidades patológicas cuyo curso se asocia al aumento de la vasculatura, tales como la degeneración macular asociada a la edad (variante húmeda), el cáncer y sus metástasis, los glaucomas neovasculares, la retinopatía diabética y del recién nacido, los procesos inflamatorios agudos y crónicos, enfermedades infecciosas, enfermedades autoinmunes, el rechazo al trasplante de órganos, los hemangiomas y los angiofibromas, entre otros.
CU20060208A 2006-11-01 2006-11-01 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) CU23636A1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CU20060208A CU23636A1 (es) 2006-11-01 2006-11-01 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
BRPI0717971-5A2A BRPI0717971A2 (pt) 2006-11-01 2007-10-30 Anticorpos recombinantes contra o fator de crescimento endotelial vascular (vegf)
CA002667594A CA2667594A1 (en) 2006-11-01 2007-10-30 Recombinant antibodies against vascular endothelial growth factor (vegf)
EP07817383A EP2093236A1 (en) 2006-11-01 2007-10-30 Recombinant antibodies against vascular endothelial growth factor (vegf)
CNA2007800437331A CN101573379A (zh) 2006-11-01 2007-10-30 针对血管内皮生长因子(vegf)的重组抗体
KR1020097011229A KR20090078363A (ko) 2006-11-01 2007-10-30 혈관 내피 성장 인자(ｖｅｇｆ)에 대한 재조합 항체
MX2009004765A MX2009004765A (es) 2006-11-01 2007-10-30 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf).
RU2009120536/10A RU2009120536A (ru) 2006-11-01 2007-10-30 Рекомбинантные антитела против васкулярного эндотелиального фактора роста (vegf)
PCT/CU2007/000019 WO2008052489A1 (es) 2006-11-01 2007-10-30 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
JP2009534978A JP2010508033A (ja) 2006-11-01 2007-10-30 血管内皮増殖因子（ｖｅｇｆ）に対する組換え抗体
AU2007315484A AU2007315484A1 (en) 2006-11-01 2007-10-30 Recombinant antibodies against vascular endothelial growth factor (VEGF)
US12/447,711 US20100151566A1 (en) 2006-11-01 2007-10-30 Recombinant antibodies against the vascular endothelial growth factor (vegf)
ARP070104873A AR063448A1 (es) 2006-11-01 2007-11-01 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
ZA200903017A ZA200903017B (en) 2006-11-01 2009-04-30 Recombinant antibodies against vascular endothelial growth factor (VEGF)
CO09056360A CO6341480A2 (es) 2006-11-01 2009-06-01 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060208A CU23636A1 (es) 2006-11-01 2006-11-01 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)

Publications (1)

Publication Number Publication Date
CU23636A1 true CU23636A1 (es) 2011-03-21

Family

ID=39148565

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060208A CU23636A1 (es) 2006-11-01 2006-11-01 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)

Country Status (15)

Country Link
US (1) US20100151566A1 (es)
EP (1) EP2093236A1 (es)
JP (1) JP2010508033A (es)
KR (1) KR20090078363A (es)
CN (1) CN101573379A (es)
AR (1) AR063448A1 (es)
AU (1) AU2007315484A1 (es)
BR (1) BRPI0717971A2 (es)
CA (1) CA2667594A1 (es)
CO (1) CO6341480A2 (es)
CU (1) CU23636A1 (es)
MX (1) MX2009004765A (es)
RU (1) RU2009120536A (es)
WO (1) WO2008052489A1 (es)
ZA (1) ZA200903017B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101093717B1 (ko) * 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
RU2412251C1 (ru) * 2009-06-15 2011-02-20 Юрий Леонидович Дорохов Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении
CU23895B1 (es) * 2010-12-28 2013-05-31 Biorec Sa Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables
CN103012588A (zh) * 2011-09-23 2013-04-03 武汉吉天朋生物科技发展有限公司 利用具有中和VEGFA生物学活性的McAb应用于肿瘤的靶向治疗
CN104073502B (zh) * 2013-03-26 2016-08-24 华东师范大学 人脑钠肽的中和性基因工程抗体3c1及其制备方法和应用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CL2014002941A1 (es) * 2014-10-30 2015-04-06 Univ Concepcion Moléculas polipeptídicas contra el factor de crecimiento del endotelio vascular (vegf)
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CU24637B1 (es) * 2019-12-24 2022-12-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen
CU24770B1 (es) 2021-12-15 2025-09-01 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69133066T2 (de) 1990-01-16 2003-03-06 Centro De Ingenieria Genetica Y Biotecnologia, Cubanacan Playa Verfahren zur Expression heterologischer Gene in der Hefe Pichia Pastoris, Expressionsverfahren und transformierte Mikroorganismen
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
CN101573379A (zh) 2009-11-04
ZA200903017B (en) 2010-03-31
AU2007315484A1 (en) 2008-05-08
WO2008052489A1 (es) 2008-05-08
BRPI0717971A2 (pt) 2013-11-12
CO6341480A2 (es) 2011-11-21
WO2008052489A8 (es) 2009-07-23
CA2667594A1 (en) 2008-05-08
JP2010508033A (ja) 2010-03-18
AR063448A1 (es) 2009-01-28
US20100151566A1 (en) 2010-06-17
EP2093236A1 (en) 2009-08-26
RU2009120536A (ru) 2010-12-10
MX2009004765A (es) 2009-06-05
KR20090078363A (ko) 2009-07-17

Similar Documents

Publication Publication Date Title
AR063448A1 (es) Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
Rossi et al. Differences and similarities between cancer and somatic stem cells: therapeutic implications
Hajizadeh-Saffar et al. Inducible VEGF expression by human embryonic stem cell-derived mesenchymal stromal cells reduces the minimal islet mass required to reverse diabetes
MX336884B (es) Expresión de il 1rap en leucemia.
Shafiee et al. Mesenchymal stem/stromal cells enhance engraftment, vasculogenic and pro-angiogenic activities of endothelial colony forming cells in immunocompetent hosts
CR20140047A (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
CU23178A1 (es) INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
Barzelay et al. Adipose‐Derived Mesenchymal Stem Cells Migrate and Rescue RPE in the Setting of Oxidative Stress
MX392416B (es) Métodos y composiciones para terapia celular adoptiva.
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
Vazquez Rodriguez et al. Adipocytes promote early steps of breast cancer cell dissemination via interleukin-8
CO7081142A2 (es) Métodos de tratamiento de enfermedades de degeneración retiniana
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
BR112015009229A2 (pt) composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
Luo et al. Hyaluronic acid facilitates angiogenesis of endothelial colony forming cell combining with mesenchymal stem cell via CD44/MicroRNA-139-5p pathway
FI3347027T3 (fi) Neo-saarekkeita käsittäen kanta- ja saarekesoluja ja diabetes mellituksen hoito niillä
EA202090966A1 (ru) МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Zhang et al. Therapeutic potential of human minor salivary gland epithelial progenitor cells in liver regeneration
MX2024004652A (es) Pautas posologicas para la movilizacion de celulas madre y progenitoras hematopoyeticas.
Liu et al. Identification of small Sca-1+, Lin−, CD45− multipotential cells in the neonatal murine retina
Notara et al. Short-term ultraviolet a irradiation leads to dysfunction of the limbal niche cells and an antilymphangiogenic and anti-inflammatory micromilieu
Stachon et al. Impact of crosslinking/riboflavin-UVA-photodynamic inactivation on viability, apoptosis and activation of human keratocytes in vitro
Sa’dyah et al. Suppression of transforming growth factor-β by mesenchymal stem-cells accelerates liver regeneration in liver fibrosis animal model
Van Pham et al. Production of endothelial progenitor cells from skin fibroblasts by direct reprogramming for clinical usages: Van Pham et al.
Van Hal et al. A system out of breath: how hypoxia possibly contributes to the pathogenesis of systemic sclerosis